lm-299 news - Search News

MSD secures worldwide license for LaNova’s LM-299

MSD has secured an exclusive worldwide license from LaNova Medicines for developing, manufacturing, and commercialising the latter’s new investigational programmed cell death 1 (PD-1)/vascular endothelial growth factor (VEGF) bispecific antibody,

Business Insider · 3d

Merck Expands Oncology Pipeline By Securing License For LaNova Medicines' LM-299

Merck & Co Inc. (MRK) and LaNova Medicines Ltd., a privately held clinical-stage biotechnology company Thursday said Merck has

MarketWatch · 3d

Merck in Cancer Licensing Pact With LaNova Medicines

Merck & Co. has struck a licensing deal with LaNova Medicines that is potentially worth more than $3 billion to the clinical-stage biotechnology company. Merck on Thursday said it has secured an exclusive global license to develop,

Reuters on MSN · 3d

Merck signs up to $3.3 billion cancer drug deal with China-based LaNova

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on Thursday. The deal allows Merck to take over development of LaNova's LM-299,

STAT · 3d

Merck licenses Chinese cancer drug, searching for next Keytruda blockbuster

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from LaNova Medicines, a Shanghai-based firm, for $588 million upfront and as much as $2.

Hosted on MSN2d

Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy

Merck MRK announced that it has entered into an exclusive licensing deal with China-based privately-held biotech company ...

MM&M3d

Merck strikes $3.3B licensing deal for Chinese cancer drug

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug ...

Merck to buy rights to Chinese cancer drug for up to $3.3B

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

Merck enters exclusive global license for LM-299

Merck (MRK) and LaNova Medicines, a privately held clinical-stage biotechnology company, announced that Merck has entered into an exclusive ...

Morningstar4d

Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd.

Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd. Merck (NYSE: MRK), known as MSD outside of the United States ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Related topics